A novel allele influencing HIV infection among injection drug users

影响注射吸毒者艾滋病毒感染的新型等位基因

基本信息

  • 批准号:
    8301750
  • 负责人:
  • 金额:
    $ 31.24万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-09-30 至 2014-06-30
  • 项目状态:
    已结题

项目摘要

Abstract Injection drug use continues to be an important factor in HIV-1 infection and transmission worldwide. Over 25% of AIDS cases in the US are currently attributable to injection drug use. HIV infection in injection drug users (IDUs) also represents a growing problem in southeast Asia and eastern Europe: In China, IDUs account for more than 50% of HIV-1 infections. Extensive population studies have demonstrated that polymorphisms in host genomes encoding chemokines and their receptors are associated with altered rates of HIV-1 infection and disease progression. However, these studies have mainly been conducted in Caucasian and African American populations. Clearly, additional genetic factors may exist in various racial and ethnic populations that can further affect HIV-1 infection and/or disease progression. Recently, we observed high frequencies of a natural complete deletion allele of the cytidine deaminase APOBEC3B (A3B) in our IDU study population in southern China. We found that people who are homozygous for the A3B deletion are significantly more resistant to HIV-1 infection than those who are homozygous for the wild-type A3B alleles (odds ratio=3 [95% confidence interval 1.2-7.5]). Furthermore, multiple regression analysis revealed significant positive associations between A3B expression and viral load set-points. APOBEC3 cytidine deaminases such as A3B are highly expressed in human T lymphocytes and macrophages. These enzymes can potentially increase HIV-1 variation by inducing cytidine deamination (C to U) during reverse transcription, resulting in G-to-A mutations in the HIV-1 genome. Certain APOBEC3 proteins also inhibit HIV-1 infection, and HIV-1 has developed a counter-defense by encoding the Vif protein. Amazingly, A3B is the only cytidine deaminase that can mutate the HIV-1 genome and be spared by HIV-1 Vif. In this application, we propose to further characterize the effects of the A3B deletion by carrying out the following specific aims: Aim 1. To further evaluate the effect of a homozygous deletion of A3B on HIV-1 infection. We will examine the effect of this naturally occurring deletion on HIV-1 infection over time among seronegative IDUs to determine whether the deletion confers persistent protection against HIV-1 infection. We will also examine more study subjects in our existing cohort to further substantiate the effect of the deletion on HIV-1 infection with the CRF08 strain. Aim 2. To determine the effect of a complete homozygous A3B deletion on infection with different HIV-1 subtypes. In particular, we will examine its effect on CRF01 and CRF08 infection among IDUs in our established cohorts. These studies will address the question of whether the effect of A3B deletion on HIV-1 infection is HIV-1 strain specific. Aim 3. To perform longitudinal observations on the effect of A3B deletion alleles on HIV-1 disease progression. The disease progression markers will be compared in HIV-1-infected individuals who are homozygous for the A3B deletion and in HIV-1-infected individuals who have at least one intact A3B gene. We will also compare the influence of the A3B deletion on HIV-1 transmission and disease progression to those of polyphorphisms in other host genetic factors, including HLA alleles, chemokines, and chemokine receptors. The proposed research is both innovative and significant in that it utilizes a unique population of subjects to dissect the influence of novel host factors on HIV-1 transmission and disease progression. A major advantage is the ability to study viral transmission and disease progression in a nascent epidemic area where HIV-1 infection has been closely followed from the beginning. Investigation of host genetic polymorphism in an understudied population by established researchers who have had extensive experience in similar types of studies in Caucasians and African Americans is a further advantage. This study should provide critical insights into the complex interplay between viral, host genetic, and behavioral factors in HIV-1 transmission and pathogenesis and may provide us with critical information regarding the design of effective intervention strategies.
摘要

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Circulating coxsackievirus A16 identified as recombinant type A human enterovirus, China.
  • DOI:
    10.3201/eid1708.101719
  • 发表时间:
    2011-08
  • 期刊:
  • 影响因子:
    11.8
  • 作者:
    Zhao K;Han X;Wang G;Hu W;Zhang W;Yu XF
  • 通讯作者:
    Yu XF
HIV-1 diversity, drug-resistant mutations, and viral evolution among high-risk individuals in phase II HIV vaccine trial sites in southern China.
  • DOI:
    10.1371/journal.pone.0068656
  • 发表时间:
    2013
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Qi H;Zhao K;Xu F;Zhang X;Zhang Z;Yang L;Li C;Liang X;Guo W;Chen S;Liu Z;Zhang W;Yu XF
  • 通讯作者:
    Yu XF
Reduced APOBEC3H variant anti-viral activities are associated with altered RNA binding activities.
  • DOI:
    10.1371/journal.pone.0038771
  • 发表时间:
    2012
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Zhen A;Du J;Zhou X;Xiong Y;Yu XF
  • 通讯作者:
    Yu XF
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Xiao-Fang Yu其他文献

Xiao-Fang Yu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Xiao-Fang Yu', 18)}}的其他基金

Identification of novel anti-HIV inhibitors based on Vif-E3 activity
基于 Vif-E3 活性鉴定新型抗 HIV 抑制剂
  • 批准号:
    8467123
  • 财政年份:
    2013
  • 资助金额:
    $ 31.24万
  • 项目类别:
Identification and characterization of novel anti-HIV inhibitors
新型抗 HIV 抑制剂的鉴定和表征
  • 批准号:
    8132453
  • 财政年份:
    2010
  • 资助金额:
    $ 31.24万
  • 项目类别:
Identification and characterization of novel anti-HIV inhibitors
新型抗 HIV 抑制剂的鉴定和表征
  • 批准号:
    8012537
  • 财政年份:
    2010
  • 资助金额:
    $ 31.24万
  • 项目类别:
Novel Small Molecule Inhibitors of HIV
新型 HIV 小分子抑制剂
  • 批准号:
    7895567
  • 财政年份:
    2009
  • 资助金额:
    $ 31.24万
  • 项目类别:
Novel Small Molecule Inhibitors of HIV
新型 HIV 小分子抑制剂
  • 批准号:
    7622255
  • 财政年份:
    2009
  • 资助金额:
    $ 31.24万
  • 项目类别:
A novel allele influencing HIV infection among injection drug users
影响注射吸毒者艾滋病毒感染的新型等位基因
  • 批准号:
    7690877
  • 财政年份:
    2008
  • 资助金额:
    $ 31.24万
  • 项目类别:
A novel allele influencing HIV infection among injection drug users
影响注射吸毒者艾滋病毒感染的新型等位基因
  • 批准号:
    7870384
  • 财政年份:
    2008
  • 资助金额:
    $ 31.24万
  • 项目类别:
A novel allele influencing HIV infection among injection drug users
影响注射吸毒者艾滋病毒感染的新型等位基因
  • 批准号:
    7595964
  • 财政年份:
    2008
  • 资助金额:
    $ 31.24万
  • 项目类别:
A novel allele influencing HIV infection among injection drug users
影响注射吸毒者艾滋病毒感染的新型等位基因
  • 批准号:
    8081858
  • 财政年份:
    2008
  • 资助金额:
    $ 31.24万
  • 项目类别:
Regulation of antiviral APOBEC3G and APOBEC3F by interferons
干扰素对抗病毒 APOBEC3G 和 APOBEC3F 的调节
  • 批准号:
    7229623
  • 财政年份:
    2007
  • 资助金额:
    $ 31.24万
  • 项目类别:

相似海外基金

Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 31.24万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
  • 批准号:
    10100360
  • 财政年份:
    2024
  • 资助金额:
    $ 31.24万
  • 项目类别:
    Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
  • 批准号:
    24K04974
  • 财政年份:
    2024
  • 资助金额:
    $ 31.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
  • 批准号:
    23K01686
  • 财政年份:
    2023
  • 资助金额:
    $ 31.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
  • 批准号:
    23K01692
  • 财政年份:
    2023
  • 资助金额:
    $ 31.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
  • 批准号:
    23K01695
  • 财政年份:
    2023
  • 资助金额:
    $ 31.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
  • 批准号:
    23K01713
  • 财政年份:
    2023
  • 资助金额:
    $ 31.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
  • 批准号:
    2312319
  • 财政年份:
    2023
  • 资助金额:
    $ 31.24万
  • 项目类别:
    Standard Grant
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
  • 批准号:
    23K01715
  • 财政年份:
    2023
  • 资助金额:
    $ 31.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
  • 批准号:
    10585388
  • 财政年份:
    2023
  • 资助金额:
    $ 31.24万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了